Search Results

You are looking at 11 - 20 of 26 items for :

  • "high-dose imatinib" x
Clear All
Full access

George D. Demetri, Margaret von Mehren, Cristina R. Antonescu, Ronald P. DeMatteo, Kristen N. Ganjoo, Robert G. Maki, Peter W.T. Pisters, Chandrajit P. Raut, Richard F. Riedel, Scott Schuetze, Hema M. Sundar, Jonathan C. Trent and Jeffrey D. Wayne

PDGFRA mutations. PFS (but not OS) for the exon 9 genotypes in this trial was significantly better in the high-dose imatinib arm (400 mg, twice daily) compared with the standard-dose arm (400 mg, daily), with a 61% reduction in relative risk ( P = .0013

Full access

Javier Pinilla-Ibarz and Alfonso Quintás-Cardama

START-C (CA180-013) [abstract] . Blood 2007 ; 110 : Abstract 734 . 51 Kantarjian H Pasquini R Levy V . Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams

Full access

Scott M. Lindhorst, Richard D. Lopez and Ronald D. Sanders

on high-dose imatinib has not been definitively established. 7 The patient tolerated initial cytoreduction with excellent response in counts. Based on initial response to therapy, consideration of upfront allogeneic hematopoietic stem cell

Full access

M. Zach Koontz, Brendan M. Visser and Pamela L. Kunz

2008 ; 26 : 626 – 632 . 10 Verweij J Casali PG Zalcberg J . Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial . Lancet 2004 ; 364 : 1127 – 1134 . 11 Dematteo RP Ballman KV

Full access

George D. Demetri, Scott Antonia, Robert S. Benjamin, Marilyn M. Bui, Ephraim S. Casper, Ernest U. Conrad III, Thomas F. DeLaney, Kristen N. Ganjoo, Martin J. Heslin, Raymond J. Hutchinson, John M. Kane III, G. Douglas Letson, Sean V. McGarry, Richard J. O'Donnell, I. Benjamin Paz, John D. Pfeifer, Raphael E. Pollock, R. Lor Randall, Richard F. Riedel, Karen D. Schupak, Herbert S. Schwartz, Katherine Thornton, Margaret von Mehren and Jeffrey Wayne

on 400 mg daily, 33% of patients who crossed over to the higher dose showed objective response rates and stable disease. However, the small advantage in progression-free survival observed for high-dose imatinib in the EORTC 62005 trial was not

Full access

Jorge Cortes, John M. Goldman and Timothy Hughes

had no clear effect regarding MMR or survival. 68 Likewise, adding pegylated IFN-α2b and granulocyte-macrophage colony-stimulating factor to high-dose imatinib did not significantly improve the cytogenetic or molecular response rates. 69 Two

Full access

Jerald P. Radich, Michael Deininger, Camille N. Abboud, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Peter Curtin, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Madan Jagasia, Hagop M. Kantarjian, Lori Maness, Leland Metheny, Joseph O. Moore, Arnel Pallera, Philip Pancari, Mrinal Patnaik, Enkhtsetseg Purev, Michal G. Rose, Neil P. Shah, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory and Hema Sundar

superior efficacy of second-generation TKIs (dasatinib, nilotinib, and bosutinib) in newly diagnosed CP-CML. Data from randomized phase III studies that have evaluated high-dose imatinib as first-line therapy for CP-CML suggest that imatinib, 800 mg, was

Full access

Michael W. Deininger, Neil P. Shah, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Lori Maness, Monica Mead, Leland Metheny, Sanjay Mohan, Joseph O. Moore, Kiran Naqvi, Vivian Oehler, Arnel M. Pallera, Mrinal Patnaik, Keith Pratz, Iskra Pusic, Michal G. Rose, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory and Hema Sundar

statistically significantly different among patients with ACA/Ph + based on TKI therapy (imatinib vs second-generation TKIs) or imatinib dose (400 vs 800 mg). It remains uncertain if second-generation TKIs or high-dose imatinib would be more beneficial for

Full access

Melanoma, Version 2.2013

Featured Updates to the NCCN Guidelines

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Dominick DiMaio, Martin D. Fleming, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Nicole McMillian and Maria Ho

. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy . Cancer 2006 ; 106 : 2005 – 2011 . 30 Ugurel S Hildenbrand R Zimpfer A . Lack of clinical efficacy of imatinib in

Full access

Arnel Pallera, Jessica K. Altman, Ellin Berman, Camille N. Abboud, Bhavana Bhatnagar, Peter Curtin, Daniel J. DeAngelo, Jason Gotlib, R. Tanner Hagelstrom, Gabriela Hobbs, Madan Jagasia, Hagop M. Kantarjian, Patricia Kropf, Leland Metheny, Joseph O. Moore, Evelena Ontiveros, Enkhtsetseg Purev, Albert Quiery, Vishnu V.B. Reddy, Michal G. Rose, Neil P. Shah, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Raoul Tibes, David T. Yang, Kristina Gregory, Hema Sundar, Michael Deininger and Jerald P. Radich

report from the Children's Oncology Group . Pediatr Blood Cancer 2011 ; 57 : 56 – 62 . 46. Giona F Putti MC Micalizzi C . Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase